Alitretinoin oral - Ligand Pharmaceuticals

Drug Profile

Alitretinoin oral - Ligand Pharmaceuticals

Alternative Names: 9-cis Retinoic acid - oral; ALRT - oral; LG 1057 - oral; LGD 1057 - oral; LGN 1057 - oral

Latest Information Update: 12 May 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals
  • Class Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists; Retinoic acid receptor antagonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute promyelocytic leukaemia; Cancer; Head and neck cancer; Kaposi's sarcoma; Lung cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Preleukaemia; Prostate cancer; Psoriasis; Renal cancer; Retinal disorders

Most Recent Events

  • 11 Sep 2003 No development reported - Phase-II for Cancer in European Union (PO)
  • 11 Sep 2003 No development reported - Phase-II for Head and neck cancer in USA (PO)
  • 11 Sep 2003 No development reported - Phase-II for Ovarian cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top